⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVL News
Nuvalent, Inc. Class A Common Stock
Form 8-K
sec.gov
NUVL
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
prnewswire.com
NUVL
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
prnewswire.com
NUVL
Form 8-K
sec.gov
NUVL
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com
NUVL
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
prnewswire.com
NUVL
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
prnewswire.com
NUVL
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
NUVL
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
globenewswire.com
RPRX
NUVL
Nuvalent Appoints Ron Squarer to Board of Directors
prnewswire.com
NUVL